Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blind parallel-group study of alternate-day versus daily roflumilast dosing in severe COPD
2011-006321-20Phase 4Completed
- Sponsor
- Andalusian Progress and Health Public Foundation
- Start
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of roflumilast in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Andalusian Progress and Health Public Foundation. Primary endpoints: Adverse events and discontinuations due to adverse events, Exacerbations and 5 more. Started Feb 2012; status: completed.
02
Drugs
roflumilast
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2011-006321-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-006321-20.